VEGFA and renal carcinoma: Despite advancements in molecular-targeted therapies and immunotherapies, such as tyrosine kinase inhibitors targeting vascular endothelial growth factor (VEGF) and immune checkpoint inhibitors4–8, advanced renal cancer remains among the most drug-resistant malignancies.